Association of Additive Risk of Pioglitazone Use with the Presence of CYP1A1 Polymorphisms in the Occurrence of Bladder Cancer

Abstract

Tumor of urinary bladder nowadays is regarded as one of the most prevalent human cancer allover our planet. Many predisposing factors play a crucial role in the pathogenesis of this tumor including endogenous and exogenous blamed causes. Certain polymorphism of CYP1A1 gene recently has been linked to the occurrence of bladder cancer. Pioglitazone that used for treatment of diabetes mellitus type II for long time carry a risk impact on induction of this tumor. Aim of this study: To evaluate the risk of using of pioglitazone in patients who carry CYP1A1 polymorphism to induce bladder carcinoma. Materials and method: This study was conducted from 2017 to 2019, 80 patients with bladder cancer after being medically diagnosed and were assessed if using of pioglitazone with presence of CYP1A1 polymorphisms associated with high risk of CA bladder. DNA was extracted and molecular detection was performed to detect single nucleotide polymorphisms (SNPs) at genetic sites using PCR and PCR-RFLP techniques. Results: There was additive risk by using of pioglitazone for long time (at least 1 year) in occurrence of CA bladder in individuals with CYP1A1 polymorphisms.